Update on AP 101 trial as a potential treatment for epidermolysis bullosa.- Amryt
Amryt announced the results of an unblinded interim efficacy analysis on its pivotal Phase III EASE trial for AP 101 as a potential treatment for Epidermolysis Bullosa (“EB”).The… read more.